Literature DB >> 11163470

The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

D E Briles1, S K Hollingshead, G S Nabors, J C Paton, A Brooks-Walter.   

Abstract

Potential vaccine strategies against otitis media are to prevent (1) symptomatic infections in the middle ear and/or (2) carriage of pneumococci and thereby subsequent middle ear infections. The possibility of using immunity to virulence proteins of pneumococci to elicit immunity against pneumococci has been examined. PspA has been found to have efficacy against otitis media in animals. Vaccination with a mixture of PsaA and PspA has been observed to offer better protection against nasal carriage in mice, than vaccination with either protein alone. PspA and pneumolysin have been shown to elicit protection against invasive infections. The inclusion of a few of these proteins into the polysaccharide-protein conjugate vaccines may be able to enhance their efficacy against otitis media and might be able to constitute a successful all-protein pneumococcal vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11163470     DOI: 10.1016/s0264-410x(00)00285-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

1.  Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin.

Authors:  Lea-Ann S Kirkham; Johanna M C Jefferies; Alison R Kerr; Yu Jing; Stuart C Clarke; Andrew Smith; Tim J Mitchell
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.

Authors:  Ankie Lebon; Nelianne J Verkaik; Joost A M Labout; Corné P de Vogel; Herbert Hooijkaas; Henri A Verbrugh; Willem J B van Wamel; Vincent W V Jaddoe; Albert Hofman; Peter W M Hermans; Jiangtao Ma; Tim J Mitchell; Henriette A Moll; Alex van Belkum
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

3.  Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias.

Authors:  J Robert Coleman; Dimitris Papamichail; Masahide Yano; María Del Mar García-Suárez; Liise-Anne Pirofski
Journal:  J Infect Dis       Date:  2011-02-21       Impact factor: 5.226

4.  Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Sarah Goetz; Sebahattin Cureoglu; Steven K Juhn; David E Briles; Michael M Paparella; Patricia Ferrieri
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-09       Impact factor: 6.223

5.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

6.  Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis.

Authors:  Wei Xin; Soo-Young Wanda; Yuhua Li; Shifeng Wang; Hua Mo; Roy Curtiss
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

7.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

Review 8.  Mouse models for human otitis media.

Authors:  Dennis R Trune; Qing Yin Zheng
Journal:  Brain Res       Date:  2009-03-06       Impact factor: 3.252

9.  Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier.

Authors:  Zeyu Chen; Rong Guo; Jianghong Xu; Chuangjun Qiu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

10.  Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition.

Authors:  M Darrieux; E N Miyaji; D M Ferreira; L M Lopes; A P Y Lopes; B Ren; D E Briles; S K Hollingshead; L C C Leite
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.